Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01523821 · ClinicalTrials.gov registry record · Phase 1
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01523821 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 20 participants.
The verdict
NCT01523821, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin (AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation.
Interventions
- DRUG Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-10-11 |
| Est. Completion | 2017-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01523821
The ClinicalTrials.gov registry entry for NCT01523821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] is the first listed.
NCT01523821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01523821 about?
NCT01523821 is a clinical study titled "Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)". This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin (AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation.
What is the current status of trial NCT01523821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-10-11. Estimated completion is 2017-01-15.
What interventions are being tested in trial NCT01523821?
The interventions under investigation include: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] (DRUG).
Who is sponsoring clinical trial NCT01523821?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.